摘要 ：近日，贵州医科大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出28项仪器试剂采购意 向，预算总额达4.16亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 贵州医科大学发布 28 项仪器 试剂 采购意向，预算总额达 3.07 亿 元，涉及高通量荧光定量 PCR系统、全 能型凝胶电泳成像系统、全能型免染蛋白印迹仪、 顶空-气相色谱仪 、多色全光谱定量型激光共聚焦、多光子及荧光 寿命显微成像系统等，预计采购时间为202 5 年 4~10 月。 贵州医科大学前身为1938年教育部直属的"国立贵阳医学院"，是当时全国最早的9所高等医学院校之一。2015年正式 更名为贵州医科大学，现为贵州省属重点高校，拥有博士后流动站3个、一级学科博士点4个、专业学位博士点1个，覆 盖医学、理学、工学等7大学科门类，形成以医学为核心、多学科交叉融合的现代学科体系。其临床医学、药学等4个 专业入选国家级特色专业，基础医学、临床医学为贵州省一流学科。 部分采购仪器介绍： 全 能型凝胶电泳成像系统 全 能 型 凝 胶 电 泳 ...

摘要 ：近日，湖北民族大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出3项仪器设备采购意向， 预算总额达1.59亿元。 学校在理工科领域拥有多个省级重点学科和培育学科，学科实力稳步提升，具体包括： 数学：入选 "十二五" 湖北省重点（培育）学科，长期深耕基础数学与应用数学研究。 计算机科学与技术：同为 "十二五" 省级重点（培育）学科，2 0 2 3 年软科中国大学学科排名进入全国前 5 0%，"十四 五" 期间获批 "湖北省属高校优势特色学科群"，获专项经费重点支持。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 湖北民族大学发布 3 项仪器设备采购意向，预算总额达 1.59亿 元，涉及购置硒资源研究与生物应用湖北省重 点实验室、生物资源保护与利用湖北省重点实验室、超轻弹性体绿色制造国家民委重点实验室、风湿性疾病发生与干预 湖北省重点实验室重大教学科研设备 ，预计采购时间为202 5 年 4~10 月。 详细采购清单： | | | | 采 | | --- | --- | --- | --- | | 采购 ...

南都讯 记者伍曼娜 近日，斯坦福大学和国际权威学术出版社爱思唯尔共同发布2025年全球前2%顶尖科 学家榜单，清华大学深圳国际研究生院（简称"清华SIGS"）入选人数再创历史新高，共26位学者入 选"终身科学影响力排行榜"，约占全院专任教师人数的10.88%；68位学者入选"年度科学影响力排行 榜"，约占全院专任教师人数的28.45%。 all University of IIII minummunum .. TH io 深圳国际研究生院 Tsinghua Shenzhen International Graduate School 14 I 251 大陆 157 17588 20 学家 据了解，该榜单分为"终身科学影响力排行榜""年度科学影响力排行榜"，从全球近700万名科学家中遴 选出世界排名前2%的科学家，涵盖22个领域和174个子领域。 全球前2%顶尖科学家榜单，通过基于其论文引用数、h因子、合著者修正的hm因子、单独或第一作者 的文章引用数等综合参数进行遴选，其中"终身影响力"榜单统计科学家职业生涯期间的综合表现，"年 度影响力"榜单则聚焦上一年度的学术影响力。 对比2024全球前2%顶尖科学家榜单 ...

通讯员孙雨晴齐鲁晚报.齐鲁壹点闫丽君 近日，烟台市卫生健康委员会公布了首批烟台市医药卫生重点学科及重点实验室(建设单位)名单。26 日，从烟台业达医院获悉，该院普通外科学成功入选，成为首批"烟台市医药卫生重点学科(建设单 位)"。这一荣誉标志着该学科在临床诊疗、科研水平、发展潜力及区域影响力等方面的综合实力获得了 权威认可。 | 序号 | 依托单位 ▼ | 学科名称 | 学科带头人 ਵ | | --- | --- | --- | --- | | 20 | 烟台市烟台山医院 | 儿科护理学 | 唐伟伟 | | 21 | 烟台业达医院 | 普通外科学 | 姜立新 | | 22 | 烟台毓璜顶医院 | 心血管外科学 | 田茂洲 | | 23 | 烟台毓璜顶医院 | 骨外科学 | 吕宏妹 | | 24 | 龙口市中医医院 | 显微外科学 | 罗伟 | | 25 | 烟台毓璜顶医院 | 生殖医学 | 包洪初 | | 26 | 烟台毓璜顶医院 | 肿瘤学 | 孙萍 | | 27 | 烟台市烟台山医院 | 运动医学 | 成功 | | 28 | 烟台市莱阳中心医院 | 急诊医学 | 徐向东 | | Sà | 烟台毓璜顶医院 ...

Core Points - The establishment of the "Shanghai Huashan Hospital Orthopedic Professor Team Studio" marks a significant collaboration between Zhenjiang Traditional Chinese and Western Medicine Hospital and Shanghai Huashan Hospital [5][7] - The collaboration aims to enhance healthcare services in the Zhenjiang region by introducing advanced techniques and standardized treatment processes from Huashan Hospital [7][11] - The partnership focuses on three core areas: discipline construction, talent cultivation, and scientific research innovation, ensuring top-tier expert resources and sustainable talent development for local orthopedic patients [11] Group 1 - The unveiling ceremony was attended by key personnel from both hospitals, highlighting the importance of this collaboration [1][5] - The collaboration will involve regular expert consultations, difficult case discussions, and high-difficulty surgical demonstrations to improve local healthcare capabilities [7][9] - The orthopedic team from Shanghai Huashan Hospital is part of the "Jinshan Talent" initiative, aimed at attracting high-level talent to Zhenjiang [11]

Core Viewpoint - Shanxi Normal University has announced two procurement intentions for scientific instruments, with a total budget of 99 million yuan, aimed at enhancing the university's teaching and research capabilities [2][3]. Procurement Overview - The procurement includes advanced scientific instruments such as a nine-channel soil carbon flux measurement system, a field emission transmission electron microscope, a high-resolution X-ray diffractometer, an atomic force microscope, a multi-channel ultrasonic testing system, and a femtosecond transient absorption spectroscopy system. The expected procurement period is from May to September 2025 [3][4][5][6]. Instrument Details - **Nine-Channel Soil Carbon Flux Measurement System**: This system is crucial for accurately measuring soil carbon flux, employing non-dispersive infrared principles to analyze CO₂ concentrations in soil, and includes multiple interfaces for connecting to various sensors [4]. - **Femtosecond Transient Absorption Spectroscopy System**: This system utilizes femtosecond laser technology to capture dynamic changes in electronic states and reaction intermediates after light excitation, serving as a core tool in fields such as chemistry and materials science [5]. - **High-Resolution X-Ray Diffractometer**: This device is essential for characterizing the microstructure of crystalline materials with significantly enhanced resolution compared to conventional X-ray diffractometers, allowing for the detection of minute structural changes [6]. Research and Development Strength - Shanxi Normal University has shown a steady increase in research capabilities, particularly in foundational disciplines, with several fields entering the top 1% globally in ESI rankings, including chemistry, engineering, and materials science [10][11]. The university has also secured numerous high-level research projects, contributing to significant advancements in various scientific domains [11]. Research Platforms - The university has established multiple provincial and national research platforms focusing on interdisciplinary areas such as molecular science, environmental pollution control, and functional materials, which support its research initiatives and enhance its academic reputation [12][13]. Future Prospects - With the ongoing construction of a new campus in Taiyuan and the promotion of "Double First-Class" initiatives, Shanxi Normal University is expected to achieve further breakthroughs in national strategic fields such as molecular science and ecological environment, contributing to regional development and ecological protection [16].

Group 1 - The core stock price of International Medical reached 5.51 yuan as of August 25, 2025, reflecting a 0.55% increase from the previous trading day, with a trading volume of 254 million yuan and a turnover rate of 2.10% [1] - The main business of International Medical is medical services, with hospitals covering comprehensive medical care and specialized diagnosis and treatment [1] - The company has been promoting business development through discipline construction and scientific research innovation in recent years [1] Group 2 - On August 22, International Medical received multiple institutional research visits, including from Tianfeng Securities, where company executives introduced the operational status for the first half of 2025, including progress in discipline construction and business layout optimization [1] - Over the past year, the company has accepted 315 research visits from 235 institutions [1] - On August 25, the net outflow of main funds was 13.6875 million yuan, with a cumulative net outflow of 6.6341 million yuan over the past five days [1]

Core Viewpoint - The performance briefing held by Xi'an International Medical Investment Co., Ltd. on August 22, 2025, highlighted the company's operational developments and financial performance for the first half of 2025, with a focus on service expansion, cost control, and strategic adjustments in response to market conditions [1]. Group 1: Operational Developments - In the first half of 2025, the company established one provincial-level clinical key specialty project and completed 636 clinical application filings for restricted technologies, along with obtaining 24 national patents and initiating 13 clinical trial projects for drugs and medical devices, indicating an expansion in academic influence [2]. - The company launched a high-end specialty service in the newly established International Medical Center Hospital and opened a 100-bed elderly care facility to address aging population needs [2]. - The company enhanced patient service experiences and smart healthcare capabilities, optimizing the entire patient service process and expanding internet hospital services [2]. Group 2: Financial Performance - In the first half of 2025, the total outpatient and emergency service volume reached 1.3191 million visits, a year-on-year increase of 5.42%, while inpatient service volume decreased by 4.01% to 96,300 visits [3]. - The company reported operating revenue of 2.0343 billion yuan, a year-on-year decrease of 15.95%, and a net profit attributable to shareholders of -164.96 million yuan, a reduction in losses by 4.98% [3]. - Operating cash flow net amount was 592.54 million yuan, an increase of 12.75% compared to the same period last year [3]. Group 3: Specific Hospital Performance - Xi'an Gaoxin Hospital recorded an outpatient and emergency service volume of 578,700 visits, with operating revenue of 638.74 million yuan, a year-on-year decrease of 17.30%, and a net profit of 30.98 million yuan, down 37.48% [4]. - Xi'an International Medical Center Hospital had an outpatient and emergency service volume of 740,500 visits, a year-on-year increase of 7.37%, but inpatient service volume decreased by 2.80% to 66,000 visits, with operating revenue of 1.3833 billion yuan, down 15.37%, and a net profit of -113.21 million yuan, a decrease of 44.63% [4]. - The company implemented cost control measures, including bed integration and department optimization, and saw an increase in the proportion of out-of-town patients, reaching 35% for Xi'an Gaoxin Hospital and 42% for Xi'an International Medical Center Hospital [4].

Group 1: Company Performance Overview - In the first half of 2025, the company achieved a total outpatient and emergency service volume of 1.3191 million, a year-on-year increase of 5.42% [4] - The company reported operating revenue of CNY 2,034.31 million, a decrease of 15.95% year-on-year, and a net profit attributable to shareholders of CNY -164.96 million, a year-on-year decrease in loss of 4.98% [4] - The operating cash flow net amount was CNY 592.54 million, an increase of 12.75% compared to the same period last year [4] Group 2: Service and Operational Improvements - The company established a senior care center with 100 beds to cater to the needs of elderly patients, including those with Alzheimer's and other disabilities [2] - The company’s hospitals completed 636 clinical application filings for restricted technologies and published 39 SCI papers, enhancing their academic influence [2] - The company improved patient service experience by optimizing the hospitalization settlement and medical insurance reimbursement processes [3] Group 3: Financial Metrics and Cost Management - In Q2 2025, the company achieved operating revenue of CNY 1.037 billion, a quarter-on-quarter increase of 4.02% [4] - The management expense ratio in Q2 was 13.12%, a decrease of 0.95 percentage points from the previous quarter [4] - The company implemented cost control measures, including optimizing personnel costs and enhancing procurement efficiency [6] Group 4: Patient Demographics and Market Reach - The proportion of out-of-town patients at Xi'an Gaoxin Hospital increased to 35%, while at Xi'an International Medical Center Hospital, it rose to 42% from less than 10% [7] - The company is adapting to DRG payment reform, stabilizing inpatient service volume while expanding outpatient services [6] Group 5: Future Outlook and Strategic Initiatives - The company plans to enhance medical quality and service experience while implementing differentiated strategies to build competitive advantages [9] - The proton therapy center, set to open in 2025, will be the first of its kind in Northwest China, significantly improving cancer treatment capabilities in the region [9]

Core Insights - The current focus of lymphoma discipline construction in China includes advancements in diagnostic and treatment technologies, as well as multi-disciplinary collaboration models [1] - The upcoming live session will feature Jin Jie, a prominent figure in the field, discussing the balance between technological empowerment and humanistic care in the medical environment [1] Group 1: Industry Developments - The level of lymphoma diagnosis and treatment in China has been continuously improving in recent years [1] - Notable breakthroughs in the industry include innovations in diagnostic and treatment technologies and collaborative models across multiple disciplines [1] Group 2: Event Details - A live discussion will take place on August 19 from 14:00 to 15:00, featuring Jin Jie, who is a distinguished professor and leader in the field of hematology [1][3] - The session aims to explore how to achieve a balance between technology and humanistic care in the current healthcare environment [1] Group 3: Access Information - Viewers can watch the live session by downloading the People's Good Doctor App and navigating to the "Famous Doctor Live" section [5] - Alternatively, viewers can follow the People's Health public WeChat account to access the app for the live broadcast [5]